Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeric and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.
1. An imidazoquinoline derived compound of Formula I, wherein Formula I has the structure:
and wherein
R is selected from the group consisting of: —NH—CO—(C 1 -C 10 alkyl), —NH—CO—(C 15 alkyl), and —NH—(C 1 -C 16 alkyl).
2. The imidazoquinoline derived compound of claim 1 , wherein R is —NH—CO—(C 1 -C 10 alkyl).
3. The imidazoquinoline derived compound of claim 1 , wherein the compound is N-(4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl)benzyl)palmitamide:
4. The imidazoquinoline derived compound of claim 1 , wherein R is —NH—(C 1 -C 16 alkyl).
5. The imidazoquinoline derived compound of claim 1 , wherein the compound is 2-butyl-1-(4-((hexadecylamino)methyl)benzyl)-1H-imidazo[4,5-c]quinolin-4-amine:
6. The imidazoquinoline derived compound of claim 1 , wherein the compound is capable of activating Toll-like receptor 7 (TLR7).
7. A pharmaceutically acceptable salt of the imidazoquinoline derived compound of any one of claims 1 - 5 .
8. The pharmaceutically acceptable salt of claim 7 , wherein the salt is obtained by reaction of the compound with a salt selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid and citric acid.
9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the pharmaceutically acceptable salt of claim 7 .
10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the imidazoquinoline derived compound of any one of claims 1 - 5 .
11. An imidazoquinoline derived compound of Formula II, wherein Formula II has the structure:
and wherein
R 1 and R 3 are H,
R 2 is C 2 -C 5 alkyl, and
R 4 is selected from the group consisting of: —NH—CO—(C 1 -C 10 alkyl), —NH—CO—(C 15 alkyl), —NH—(C 1 -C 16 alkyl), and NH 2 .
12. The imidazoquinoline derived compound of claim 11 , wherein R 2 is C 4 alkyl.
13. The imidazoquinoline derived compound of claim 11 , wherein the compound is 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine:
14. The imidazoquinoline derived compound of claim 11 , wherein the compound is 1-(3-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine:
15. The imidazoquinoline derived compound of claim 11 , wherein the compound is capable of activating TLR7 and TLR8.
16. A pharmaceutically acceptable salt of the imidazoquinoline derived compound of any one of claims 11 - 14 .
17. The pharmaceutically acceptable salt of claim 16 , wherein the salt is obtained by reaction of the compound with a salt selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, malic acid, maleic acid, succinic acid, tartaric acid and citric acid.
18. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the pharmaceutically acceptable salt of claim 16 .
19. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the imidazoquinoline derived compound of any one of claims 11 - 14 .